Johnson & Johnson Acquires Proteologix Inc.

Eli Lilly Acquires Protomer Technologies

July 14, 2021

Biotechnology

Eli Lilly and Company announced the acquisition of Protomer Technologies, a private biotechnology company based in Pasadena, California, to enhance Lilly's diabetes pipeline. The deal has potential value of over $1 billion contingent on development and commercial milestones; Lilly previously held a 14% stake and is acquiring the remaining shares to gain Protomer's glucose‑sensing insulin programs and protein‑engineering MEPS platform.

Johnson & Johnson Acquires Yellow Jersey Therapeutics from Numab for $1.25B

May 28, 2024

Biotechnology

Johnson & Johnson agreed to acquire Yellow Jersey Therapeutics, a wholly owned spin-off of Numab Therapeutics, for $1.25 billion in cash to obtain global rights to NM26, a Phase‑2‑ready bispecific antibody for atopic dermatitis. The deal was announced May 28, 2024 (Numab/ Novo Holdings) and completed in July 2024; J&J will develop, manufacture and commercialize NM26 globally.

Otsuka Pharmaceutical Acquires Jnana Therapeutics

August 1, 2024

Biotechnology

Otsuka Pharmaceutical Co., Ltd. will acquire clinical-stage biotech Jnana Therapeutics, making it a wholly owned subsidiary via Otsuka America, Inc. The deal values Jnana at $800 million in upfront cash plus up to $325 million in development and regulatory milestones and is intended to add Jnana's RAPID chemoproteomics platform and lead program JNT-517 (a potential oral PKU therapy) to Otsuka's specialty and autoimmune pipeline.

Shionogi Inc. Acquires Qpex Biopharma, Inc.

June 26, 2023

Pharmaceuticals

Shionogi Inc., the U.S. subsidiary of Shionogi & Co., Ltd., entered into a definitive agreement to acquire San Diego-based clinical-stage antimicrobial developer Qpex Biopharma, Inc. The acquisition (upfront $100 million plus up to $40 million in milestones) brings Qpex's investigational beta-lactamase inhibitor xeruborbactam and expands Shionogi's infectious disease R&D capabilities and pipeline.

Servier Acquires Symphogen A/S from Novo Holdings and Other Owners

April 3, 2020

Biotechnology

Servier has acquired 100% of the share capital of Symphogen A/S from Novo Holdings and the remaining owners, taking ownership of the Danish therapeutic antibody discovery and early biologics development company. The deal brings Symphogen’s antibody discovery platform and CMC biologics development capabilities into Servier’s oncology and immuno-oncology R&D efforts to strengthen its biologics pipeline and development capacity.

Inotiv Acquires Protypia to Expand Protein/Peptide Bioanalytical Capabilities

July 7, 2022

Healthcare Services

Inotiv, Inc. completed the acquisition of Nashville-based Protypia, Inc., a protein/peptide bioanalytical company, for approximately $11.0 million in a combination of cash, Inotiv common shares and promissory notes. The deal adds quantitative tissue-based large-molecule mass spectrometry capabilities to Inotiv's bioanalytical offerings to support immuno-oncology, cell and gene therapy, and other drug development programs.